Latest news with #epilepsy
Yahoo
9 hours ago
- Health
- Yahoo
Footballer, 27, found dead in bath days after stopping medication
A 'fit and healthy' footballer was found dead in her bath days after she stopped taking medication for epilepsy, an inquest has heard. Emily Wilcock, who played for Bury Football Club's Women Green team, died on August 21, 2023 at the age of 27. Her partner, with whom she was planning start a family, found her unresponsive in the bath at their home in Earls Close, Radcliffe. However, post-mortem examinations did not find evidence to conclude that Emily had drowned. Instead, senior coroner Joanne Kearsley, who described the case as 'very unusual and very rare', concluded that Emily died from 'natural causes' linked to epilepsy. READ MORE: 'I'm not convinced you really understand how inappropriate this was and I don't think you feel sorry about it' READ MORE: 'Amazing' RAF technician, 20, died on deployment months after devastating loss The conclusion came after Rochdale Coroner's Court heard on Monday (July 28) that Emily had stopped taking medication days earlier. Sign up to the MEN Court newsletter here The 27-year-old from Bury had been taking a 'minimal' dose of anti-epilepsy medication Lamotrigine since 2016 when her twin brother found her foaming at the mouth after sunbathing at their home before she had another suspected seizure in September of that year. She later experienced what her mum described as 'blackouts' which would be over 'within seconds'. However, despite experiencing these episodes of fainting, the inquest heard that her doctor had doubts over whether her initial diagnosis of epilepsy was correct. Sophie came off Lamotrigine in July 2023 having first discussed her medication and its impact on pregnancy with her doctor in January. Dr Nazar Sharaf, a consultant neurologist at the Northern Care Alliance, told the inquest that Emily's 'minimal' dose of Lamotrigine - which was just 50mg a day - was so small that she could stop taking the medication immediately without weaning herself off it. Within days of her coming off the medication, Emily, who was described by her sister as 'fit and healthy', was found dead in her bath. Her partner James discovered her in the bath after he returned home from work, called 999 and performed CPR on her, but to no avail. Dr Emil Salmo, a consultant pathologist based at the Royal Oldham Hospital, told the inquest that evidence of tongue biting and 'clenching of the jaw' was found during the post-mortem, but there was no evidence of 'trauma' during these examinations. He explained that Emily's lungs were 'slightly above normal' in size but said that this was not enough to conclude that she drowned. Dr Daniel du Plessis, a consultant neuropathologist, told the inquest that, after investigating other possible causes of death, including issues with her heart, but failing to obtain any positive results, he concluded that Emily died by Sudden Unexpected Death in Epilepsy. Ms Kearsley, who is the senior coroner for the Manchester North district, accepted his conclusion which he said was on a 'knife edge'. She explained that she may have reached a different conclusion had Emily stopped taking her medication a year before she died. But she told the family that, despite the timing 'tipping the balance', she could not say whether Emily's death could have been prevented had she continued taking the medication. She said: "My conclusion is that Emily died as a result of natural causes. There was nothing unnatural about her death." Addressing Emily's partner, she said: "I can see how missed she is and I know how difficult that night must have been for you. "Go and remember Emily as she was and all the good things about her." Paying tribute to Emily, her sister Sophie Wilcock, said: "She was my little sister. She was very sporty - she played football. "I was always the talkative one growing up, but she was very, very protective and willing to speak out, especially when I do things wrong. "She was so loving. So many people loved her." Following her death, Bury Football Club also paid tribute to Emily. In a statement posted on their website, the club said: "Everyone who knew Emily will know she was such a lovely person with a great personality and always had a big smile on her face."
Zawya
15 hours ago
- Health
- Zawya
Vinmec Central Park Performs Vietnam's First SEEG using AutoGuide Robotic Guidance System for a child diagnosed from refractory epilepsy
HO CHI MINH CITY, VIETNAM - Media OutReach Newswire - 29 July 2025 – A major breakthrough in Vietnam's neurological treatment was recently achieved as doctors at Vinmec Central Park International Hospital successfully performed surgery on a 9-year-old boy with drug-resistant epilepsy, utilizing the AutoGuide™ robotic Guidance system for SEEG implantation. This marks the first time in Vietnam that robotic guidance has been used in pediatric epilepsy surgery, — a milestone that opens new possibilities for safer, less invasive, and highly precise treatment options for vulnerable patients. The case also highlights Vietnam's progress in approaching global standards in advanced epilepsy care. A 5-Year Search for Seizure-Free Sleep The patient, B.Q.K. (age 9, from Hanoi), began experiencing seizures in 2021. Despite various treatment regimens and adjustments both domestically and abroad, his condition failed to improve - sometimes experiencing dozens of seizures per day. For nearly five years, his family sought treatment at numerous medical centers in the hope of giving their child a peaceful night's sleep without seizures. According to the World Health Organization (WHO), approximately 30% of epilepsy patients are drug-resistant (1), meaning they do not respond to medication. For these patients, surgery resection of the epileptic zone is often the most effective option. However, accurately localizing the epileptogenic zone - especially in children - is extremely challenging when scalp EEG, MRI, or PET scans provide inconclusive findings. SEEG and AutoGuide: A Technological Duo to Precisely Locate the "Culprit" in the Brain Following a thorough multidisciplinary evaluation, doctors at Vinmec Central Park decided to use AutoGuide™ robotic navigation system to perform stereo-electroencephalography (SEEG) to accurately identify the epileptic zone. The robotic guidance ensured high accuracy, faster operative time, and reduced trauma to the brain. After seven days of SEEG monitoring, the epileptogenic zone was localized in the right orbitofrontal cortex and inferior frontal gyrus—areas densely packed with neural pathways and blood vessels. On June 17, 2025, the epileptic zone removal was performed by Dr. Truong Van Tri and his team at Vinmec Central Park, with technical support from Assoc. Prof. Dr. Shunsuke Nakae, an epilepsy specialist from Japan. The surgery was successful, with no postoperative neurological deficits. After more than one month of recovery, the patient resumed normal activities and play, with only two minor nocturnal seizures recorded - a reduction of over 95% compared to preoperative frequency. " For the first time, we achieved near-perfect outcome in pediatric epilepsy surgery thanks to AutoGuide™. This is a critical milestone, especially for young patients who are highly vulnerable to major brain surgery," said Dr. Tri. Vinmec: Advancing Neurology with Technology and International Integration This successful case exemplifies Vinmec's strategy to build centers of medical excellence through the integration of advanced technology, multidisciplinary expertise, and individualized treatment protocols. Vinmec has been ranked as the No.1 private hospital system in Vietnam for expatriates and international visitors, according to independent patient satisfaction surveys. Vinmec Central Park is currently one of the few healthcare facilities in Vietnam, placing Vietnam among the few countries in Asia to master this technique—narrowing the gap with global neurology leaders. (1) Hashtag: #Vinmec The issuer is solely responsible for the content of this announcement. About Vinmec Health System Vinmec is a nonprofit healthcare system founded by Vingroup, one of Vietnam's largest private conglomerates. With 9 international hospitals and 4 international clinics nationwide, Vinmec is committed to delivering international-standard healthcare through subspecialized care, personalized treatment, and cutting-edge medical technology. Vinmec Central Park in Ho Chi Minh City is the flagship hospital in the network and has been widely recognized as the top private hospital in Vietnam for expatriates and international patients, serving tens of thousands annually. The hospital excels across several specialties: Neurosurgery & Epilepsy: SEEG, robotic-guided surgery, brain tumor resection Oncology – Orthopedic Surgery – Cardiology – Advanced Obstetrics & Gynecology Allergy & Clinical Immunology: Vietnam's first and only center recognized as a Center of Excellence by the World Allergy Organization (WAO), in close partnership with Cleveland Clinic (USA) to develop precision medicine and chronic disease management programs 3D Medical Technology: Pioneer in 3D-printed titanium implants for complex orthopedic oncology reconstructions Vinmec
Malay Mail
17 hours ago
- Health
- Malay Mail
Vinmec Central Park Performs Vietnam's First SEEG using AutoGuide Robotic Guidance System for a child diagnosed from refractory epilepsy
The patient recovered quickly after surgery. This marks the first time in Vietnam that robotic guidance has been used in pediatric epilepsy surgery, — a milestone that opens new possibilities for safer, less invasive, and highly precise treatment options for vulnerable patients. The case also highlights Vietnam's progress in approaching global standards in advanced epilepsy care. A 5-Year Search for Seizure-Free Sleep The patient, B.Q.K. (age 9, from Hanoi), began experiencing seizures in 2021. Despite various treatment regimens and adjustments both domestically and abroad, his condition failed to improve - sometimes experiencing dozens of seizures per day. For nearly five years, his family sought treatment at numerous medical centers in the hope of giving their child a peaceful night's sleep without seizures. According to the World Health Organization (WHO), approximately 30% of epilepsy patients are drug-resistant (1), meaning they do not respond to medication. For these patients, surgery resection of the epileptic zone is often the most effective option. However, accurately localizing the epileptogenic zone - especially in children - is extremely challenging when scalp EEG, MRI, or PET scans provide inconclusive findings. SEEG and AutoGuide: A Technological Duo to Precisely Locate the "Culprit" in the Brain Following a thorough multidisciplinary evaluation, doctors at Vinmec Central Park decided to use AutoGuide™ robotic navigation system to perform stereo-electroencephalography (SEEG) to accurately identify the epileptic zone. The robotic guidance ensured high accuracy, faster operative time, and reduced trauma to the brain. After seven days of SEEG monitoring, the epileptogenic zone was localized in the right orbitofrontal cortex and inferior frontal gyrus—areas densely packed with neural pathways and blood vessels. On June 17, 2025, the epileptic zone removal was performed by Dr. Truong Van Tri and his team at Vinmec Central Park, with technical support from Assoc. Prof. Dr. Shunsuke Nakae, an epilepsy specialist from Japan. The surgery was successful, with no postoperative neurological deficits. After more than one month of recovery, the patient resumed normal activities and play, with only two minor nocturnal seizures recorded - a reduction of over 95% compared to preoperative frequency. "For the first time, we achieved near-perfect outcome in pediatric epilepsy surgery thanks to AutoGuide™. This is a critical milestone, especially for young patients who are highly vulnerable to major brain surgery," said Dr. Tri. Vinmec: Advancing Neurology with Technology and International Integration This successful case exemplifies Vinmec's strategy to build centers of medical excellence through the integration of advanced technology, multidisciplinary expertise, and individualized treatment protocols. Vinmec has been ranked as the No.1 private hospital system in Vietnam for expatriates and international visitors, according to independent patient satisfaction surveys. Vinmec Central Park is currently one of the few healthcare facilities in Vietnam, placing Vietnam among the few countries in Asia to master this technique—narrowing the gap with global neurology leaders. (1) HO CHI MINH CITY, VIETNAM - Media OutReach Newswire - 29 July 2025 – A major breakthrough in Vietnam's neurological treatment was recently achieved as doctors at Vinmec Central Park International Hospital successfully performed surgery on a 9-year-old boy with drug-resistant epilepsy, utilizing the AutoGuide™ robotic Guidance system for SEEG marks the first time in Vietnam that robotic guidance has been used in pediatric epilepsy surgery, — a milestone that opens new possibilities for safer, less invasive, and highly precise treatment options for vulnerable patients. The case also highlights Vietnam's progress in approaching global standards in advanced epilepsy patient, B.Q.K. (age 9, from Hanoi), began experiencing seizures in 2021. Despite various treatment regimens and adjustments both domestically and abroad, his condition failed to improve - sometimes experiencing dozens of seizures per nearly five years, his family sought treatment at numerous medical centers in the hope of giving their child a peaceful night's sleep without to the World Health Organization (WHO), approximately 30% of epilepsy patients are drug-resistant, meaning they do not respond to medication. For these patients, surgery resection of the epileptic zone is often the most effective option. However, accurately localizing the epileptogenic zone - especially in children - is extremely challenging when scalp EEG, MRI, or PET scans provide inconclusive a thorough multidisciplinary evaluation, doctors at Vinmec Central Park decided to use AutoGuide™ robotic navigation system to perform stereo-electroencephalography (SEEG) to accurately identify the epileptic zone. The robotic guidance ensured high accuracy, faster operative time, and reduced trauma to the seven days of SEEG monitoring, the epileptogenic zone was localized in the right orbitofrontal cortex and inferior frontal gyrus—areas densely packed with neural pathways and blood vessels. On June 17, 2025, the epileptic zone removal was performed by Dr. Truong Van Tri and his team at Vinmec Central Park, with technical support from Assoc. Prof. Dr. Shunsuke Nakae, an epilepsy specialist from surgery was successful, with no postoperative neurological deficits. After more than one month of recovery, the patient resumed normal activities and play, with only two minor nocturnal seizures recorded - a reduction of over 95% compared to preoperative successful case exemplifies Vinmec's strategy to build centers of medical excellence through the integration of advanced technology, multidisciplinary expertise, and individualized treatment protocols. Vinmec has been ranked as the No.1 private hospital system in Vietnam for expatriates and international visitors, according to independent patient satisfaction Central Park is currently one of the few healthcare facilities in Vietnam, placing Vietnam among the few countries in Asia to master this technique—narrowing the gap with global neurology Hashtag: #Vinmec The issuer is solely responsible for the content of this announcement. About Vinmec Health System Vinmec is a nonprofit healthcare system founded by Vingroup, one of Vietnam's largest private conglomerates. With 9 international hospitals and 4 international clinics nationwide, Vinmec is committed to delivering international-standard healthcare through subspecialized care, personalized treatment, and cutting-edge medical technology. Vinmec Central Park in Ho Chi Minh City is the flagship hospital in the network and has been widely recognized as the top private hospital in Vietnam for expatriates and international patients, serving tens of thousands annually. The hospital excels across several specialties: Neurosurgery & Epilepsy: SEEG, robotic-guided surgery, brain tumor resection Oncology – Orthopedic Surgery – Cardiology – Advanced Obstetrics & Gynecology Allergy & Clinical Immunology: Vietnam's first and only center recognized as a Center of Excellence by the World Allergy Organization (WAO), in close partnership with Cleveland Clinic (USA) to develop precision medicine and chronic disease management programs 3D Medical Technology: Pioneer in 3D-printed titanium implants for complex orthopedic oncology reconstructions
Yahoo
21 hours ago
- Health
- Yahoo
My Son And I Were Turned Away From Ikea's Play Area For 1 Disturbing Reason. Here's What They Don't Understand.
In late June, a few days before Disability Pride Month began, I took my 7-year-old child on an outing to an Ikea store. As I filled out a waiver so he could enter the store's small play area, I noticed I was the only parent present. It turned out that parents typically drop off their children while they shop, but that wasn't an option for me. My son has a rare, severe form of epilepsy called Dravet syndrome, among other medical conditions, and he can't be without a grown-up carrying his seizure rescue medication, as I was. The scary reality is that around one in five children with Dravet syndrome die in childhood because the seizures can be so severe. There is currently no cure. I explained this to a staff member and told her that I'd need to be in the room with my child. She informed me that no parents were allowed into the play area. 'But isn't there a policy for kids with disabilities?' I asked. She told me a service dog could accompany a child, but a parent could not. I stopped signing the form. I said to the staff member, 'That's discrimination against kids with disabilities.' She didn't respond. I hadn't known about the store's play area before this visit, and I had been happy to see that it wasn't a playground ― just a space with toys like a train set and dart board. Since my son had a seizure at an indoor playground a year ago, I'd stopped taking him to them. But now, even this play space was not an option for him. My child and I were both upset. He loves going to Ikea to walk through the showroom and eat in the cafeteria ― a place open enough that it was the only indoor restaurant he ate in during our four years of masking during the COVID-19 pandemic. We have several Ikea furniture items, including bunk beds, a coat/shoe cubby and a toy chest. He helped us build them all. Since his severe seizures began about two years ago, he's had to change his life in significant ways. Heat, sports, just running around to play, illness and excitement have all become triggers for him. Summer is especially hard — on hot days, he can't be outside. In fact, we had driven the hour to Ikea in traffic just so he could walk and have a change of scenery in a large, air-conditioned space because the temperature outside was dangerous for him. I told him, 'This isn't OK.' He said, 'We should talk to someone.' I was proud of him. After talking to a few staff members, we spoke with a manager, who said he wasn't familiar with the policy, and he'd get back to me the next day. He didn't. Later, I looked online, and there was a section on the Ikea website directing caretakers of children with disabilities to start a conversation with the Ikea store manager about how the child can best have their needs accommodated in the play area. I was hopeful that when we went in the future, we could show the policy to the staff. However, that doesn't undo the pain my child felt after hearing that he wasn't welcome in that play space because of his disabilities. During the hour-long car ride home afterward, we talked a lot about discrimination. I reinforced that what happened wasn't OK, and that the more than 3 million kids with disabilities in our country deserve to be included. I told him about my older sister, his late aunt, who had microcephaly and faced various barriers to equal access too, like having to sit on the sidelines of playgrounds in her wheelchair. It upset me. When I was 10 in 1993, I read about new accessible playgrounds in an issue of Scholastic News, and I hoped we could build one for her. Sadly, she died a few weeks later, but in her memory, my family and I worked with the Cincinnati Parks Department to build an accessible playground. My son thought that was cool. I also explained that many groups of people face discrimination for reasons such as gender, race, sexual orientation, immigration status and more, and we need to be allies and stand up against all forms of discrimination. I also told him that one way to help is to make disabilities more visible and raise awareness, as we have done in his school class for the past three years. This June, for Dravet Syndrome Awareness Month, he and I held a neighborhood lemonade and cupcake fundraiser and donated money to the Dravet Syndrome Foundation, which helps fund the kind of critical epilepsy research that the Trump administration has recently cut. After our experience at Ikea, as one of his bedtime books, we re-read the picture book 'All the Way to the Top,' about a child who protested and helped advocate for the Americans with Disabilities Act, which passed 35 years ago. Afterward, I told him about children with disabilities who went to Congress this summer, asking their leaders not to make it harder for them to go to the doctor and get the medicine and treatment they need. Unfortunately, President Donald Trump's domestic policy billhas since passed, and many people, including children with disabilities, will be harmed as a result. Two days after the bill passed, my child woke up and said, 'I want to make a sign about disabilities.' He asked for my help with spelling before writing the words 'People with disabilities are important' in pencil and then tracing over them with marker. He stood by our Disability Pride yard sign, and then, since the temperature was cooler out, he walked down our street and held it up for cars passing by. He said that when he grows up, he wants to be an 'activist' and 'protester.' I told him that he already is. [Editor's Note: HuffPost reached out for a response, and Ikea US issued the following statement: 'At IKEA, we strive to offer a safe and inclusive environment for children to play while in our stores. Our Småland policies are in place to keep children safe when they are in our space. Regarding this family's recent experience in our College Park, MD store, we are incredibly sensitive to feelings of exclusion, and so we have shared information with the family about our accommodations process, so that they may have a more positive experience at IKEA. We are constantly working to improve how we create an inclusive space while maintaining policies that keep all children safe.'] Do you have a compelling personal story you'd like to see published on HuffPost? Find out what we're looking for here and send us a pitch at pitch@
Yahoo
4 days ago
- Business
- Yahoo
Rising Clinical Trials, R&D Activities, and Commercialization of Cannabis-based Indications
Global medical cannabis market to hit USD 68.6 billion by 2033, growing at a 7.1% CAGR. Key growth drivers include increasing legalization and therapeutic use for conditions like chronic pain and epilepsy. North America leads due to progressive regulations. Top players like Canopy Growth and GW Pharmaceuticals drive innovation in the sector. Medical Cannabis Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Medical Cannabis Market Report 2025-2033" report has been added to global medical cannabis market size reached USD 37.0 Billion in 2024. Looking forward, the publisher expects the market to reach USD 68.6 Billion by 2033, exhibiting a growth rate (CAGR) of 7.1% during 2025-2033. The increasing product use in treating substance use disorders, the exploration of products for chronic inflammatory conditions, the rising product demand for gastrointestinal disorders, and the rising demand for CBD-based products are some of the factors propelling the market. The global market is majorly driven by the increasing acceptance of the product for medicinal purposes. In line with this, the expanding legalization of the product is significantly contributing to the market. Furthermore, the rising awareness of the potential therapeutic benefits of the product is positively influencing the market. Apart from this, the rapid advancements in cannabis research and medical studies are offering numerous opportunities for the market. Moreover, the growing prevalence of chronic pain and other medical conditions treatable with the product is catalyzing the market. Besides, the escalating aging population seeking alternative treatments for age-related ailments is propelling the market. The opioid crisis and the search for safer pain management options are bolstering the market. Additionally, the increasing demand for natural and plant-based medicines is providing a boost to the market. Competitive Landscape: Top companies are strengthening the market by leveraging their resources, expertise, and brand recognition. These companies invest heavily in research and development to create innovative cannabis-based products with consistent quality and efficacy. They expand their presence in key markets through strategic partnerships and acquisitions, driving consumer awareness and accessibility. Their established distribution networks enable the widespread availability of medical cannabis products, reaching a broader patient base. Furthermore, these companies also engage in educational initiatives to raise awareness among healthcare professionals and the general public about the therapeutic potential of medical cannabis. Their efforts to comply with regulatory standards and maintain product safety build trust and credibility in the industry. By setting high industry standards and fostering best practices, these companies contribute to the market growth, leading the way for continued expansion and acceptance of medical cannabis as a legitimate and effective treatment option. North America exhibits a clear dominance, accounting for the largest medical cannabis market shareNorth America is fostering the market growth due to its progressive regulatory environment, increasing acceptance, and widespread legalization across various states and countries in the region. In particular, the United States and Canada have been at the forefront of the medical cannabis movement, with many states and provinces legalizing medical cannabis for therapeutic use. The growing awareness and acceptance of medical cannabis have increased patient demand as individuals seek alternative treatments for various medical conditions. This increasing demand, in turn, has spurred investments in research, development, and commercialization of medical cannabis products, driving market well-established pharmaceutical companies and research institutions in North America have accelerated the development of standardized and regulated cannabis-based medications, further propelling market expansion. The evolving legal landscape, coupled with a strong consumer base and supportive healthcare policies, positions North America as a significant driving force behind the market's global Cannabis Market Trends/Drivers: Rising clinical trials, research and development (R&D) activities, and commercialization of cannabis-based indicationsThe rising clinical trials, research and development (R&D) activities, and commercialization of cannabis-based indications are fostering the market. With increasing acceptance and legalization, there is a growing interest among researchers, pharmaceutical companies, and medical professionals to explore the potential therapeutic benefits of the product. Clinical trials and research studies are essential to provide scientific evidence supporting the efficacy and safety of cannabis-based treatments for various medical conditions. As more positive results emerge from these studies, confidence in medical cannabis as a legitimate treatment options increases, leading to wider adoption. Furthermore, commercializing cannabis-based indications has seen substantial investments from pharmaceutical companies and startups. The development of standardized cannabis-based pharmaceutical products offers more consistent dosing, quality control, and regulatory compliance, further legitimizing the product in the healthcare industry. As the product becomes more firmly integrated into mainstream medicine, the market is expected to expand, attracting more patients, healthcare providers, and investors. This positive momentum in research, development, and commercialization fuels the disposable incomes of the consumersThe inflating disposable incomes of the consumers are favorably impacting the market. As disposable incomes rise, consumers have more financial capacity to spend on healthcare, including alternative and complementary treatments. With increased purchasing power, individuals are more likely to explore and invest in the product for various health conditions. Medical cannabis, which may not be covered by insurance in some regions, can become a viable option for consumers with higher disposable incomes. Inflating disposable incomes also contribute to a shift in consumer preferences towards more holistic and natural health remedies. As individuals prioritize their well-being, they seek alternative treatments beyond traditional pharmaceuticals, leading to increased demand for the product. Additionally, higher disposable incomes allow consumers to afford these products that may be of higher quality or from reputable sources, boosting the premium segment of the emergence of new cannabis-based pharmaceutical productsThe emergence of new cannabis-based pharmaceutical products is bolstering the market. As research and clinical trials continue to explore the therapeutic potential of cannabinoids and other cannabis-derived compounds, pharmaceutical companies are developing innovative cannabis-based medications. These new pharmaceutical products undergo rigorous testing and regulatory approvals, instilling confidence in medical professionals and patients about their safety and efficacy. As a result, more healthcare providers are open to prescribing cannabis-based medications for various medical conditions, thus driving market adoption. The development of standardized cannabis-based pharmaceuticals also addresses concerns about dosage consistency and quality control, making them more reliable and appealing to patients and healthcare providers. Moreover, the emergence of new cannabis-based medications expands the potential applications of medical cannabis in treating a wide range of conditions, from chronic pain and neurological disorders to mental health ailments. Key Attributes: Report Attribute Details No. of Pages 125 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $37 Billion Forecasted Market Value (USD) by 2033 $68.6 Billion Compound Annual Growth Rate 7.1% Regions Covered Global Detailed Profiles of All Major Companies Canopy Growth Corporation GW Pharmaceuticals, plc Aurora Cannabis, Inc. Aphria, Inc. MedReleaf Corporation Insys Therapeutics, Inc. CanniMed Therapeutics, Inc. Cara Therapeutics, Inc. United Cannabis Corporation Medical Cannabis Industry Segmentation:Breakup by Species: Indica Sativa Hybrid Breakup by Derivatives: Cannabidiol (CBD) Tetrahydrocannabinol (THC) Others Breakup by Application: Cancer Arthritis Migraine Epilepsy Others Breakup by End-Use: Pharmaceutical Industry Research and Development Centres Others Breakup by Route of Administration: Oral Solutions and Capsules Vaporizers Topicals Others Breakup by Region: North America United States Canada Asia-Pacific Europe Germany France Italy Spain Netherlands Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Medical Cannabis Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
